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Introduction
 The number of patients with osteoporotic fractures is increasing[1]. The occurrence 
of hip fractures in the Netherlands is expected to increase by 230 every year up to 
23,900 in the year 2020[2]. The prevalence of vulnerability among the elderly is also 
increasing, with an average prevalence of 14.5% among men over 65 and 20.7% among 
women over 65[3]. Vulnerability is defined as a person’s diminishing ability – occurring 
in several areas simultaneously – to resist physical strain and threats resulting from 
environmental factors, coupled with a loss of both physical and mental vitality[3]. The 
chance of complications during clinical treatments and readmissions is clearly elevated 
among vulnerable patients. The optimisation of healthcare is therefore vital in order to 
decrease morbidity and mortality[3-5]. Healthcare can be improved by implementing a 
multidisciplinary treatment concept, recorded in medical, paramedical and nursing care 
pathways such as those used for injuries and fractures in the Geriatric Trauma Unit (GTU)
[6-8]. The beneficial results of this approach have already been published[6]. 
 Osteoporosis screening among elderly patients with low-energy fractures is an 
important component of the optimisation of healthcare within the GTU and is best done 
via a Fracture Prevention outpatient clinic (FP clinic), where the bone mineral density 
(BMD) is measured with Dual Energy X-ray Absorptiometry (DXA)[9-11]. Although fracture 
patients are actively referred from the GTU to our hospital’s FP clinic, only 44% of these 
patients actually showed up in the clinic[12]. An earlier study described how most patients 
opted out of an osteoporosis screening for various reasons: a lack of interest resulting from 
insufficient knowledge concerning the importance of the osteoporosis screening (38%), 
being physically incapable of visiting the FP clinic (11.5%) or being unavailable for setting an 
appointment (23.8%)[13]. The percentage of patients that can be screened for osteoporosis 
will therefore increase when such screenings take place during the hospital admission. 
 Conducting a DXA scan during the admission is often not feasible for logistical and 
technical reasons. A peripheral DXA scan can be used to determine the BMD in the 
nursing ward during the admission[14]. Earlier studies already showed that the Calscan, a 
peripheral DXA scanner, can be used to reliably classify patients with a normal BMD and 
patients with osteoporosis[15,16]. It has also been demonstrated that a BMD measurement 
at the level of the calcaneus is as good an indicator of the risk of a future osteoporotic 
fracture as a BMD measurement of the hip or spinal column[11,17,18].  In February of 2013, 
we therefore began using the Calscan in the nursing ward of our hospital on patients 
admitted for the treatment of a low-energy fracture. If they are definitely classified as 
osteoporotic based on the Calscan T-score, a treatment was initiated. Because it proved 
impossible, for various reasons, to classify all patients during their admission – even with 
the use of the Calscan – and because a BMD measurement with a DXA scan is still the 
golden standard, all patients were also referred to the FP clinic to undergo a DXA scan. 
The final treatment plan was drawn up based on the results of this DXA scan.
 The goal of this study was to evaluate whether the percentage of patients that can be 
classified and treated will increase when the Calscan is used in the osteoporosis screening 
process. Furthermore, the study was designed to provide more insight into why and which 
patients opt out of a screening for osteoporosis.
76 Chapter 6
Introduction
 The number of patients with osteoporotic fractures is increasing[1]. The occurrence 
of hip fractures in the Netherlands is expected to increase by 230 every year up to 
23,900 in the year 2020[2]. The prevalence of vulnerability among the elderly is also 
increasing, with an average prevalence of 14.5% among men over 65 and 20.7% among 
women over 65[3]. Vulnerability is defined as a person’s diminishing ability – occurring 
in several areas simultaneously – to resist physical strain and threats resulting from 
environmental factors, coupled with a loss of both physical and mental vitality[3]. The 
chance of complications during clinical treatments and readmissions is clearly elevated 
among vulnerable patients. The optimisation of healthcare is therefore vital in order to 
decrease morbidity and mortality[3-5]. Healthcare can be improved by implementing a 
multidisciplinary treatment concept, recorded in medical, paramedical and nursing care 
pathways such as those used for injuries and fractures in the Geriatric Trauma Unit (GTU)
[6-8]. The beneficial results of this approach have already been published[6]. 
 Osteoporosis screening among elderly patients with low-energy fractures is an 
important component of the optimisation of healthcare within the GTU and is best done 
via a Fracture Prevention outpatient clinic (FP clinic), where the bone mineral density 
(BMD) is measured with Dual Energy X-ray Absorptiometry (DXA)[9-11]. Although fracture 
patients are actively referred from the GTU to our hospital’s FP clinic, only 44% of these 
patients actually showed up in the clinic[12]. An earlier study described how most patients 
opted out of an osteoporosis screening for various reasons: a lack of interest resulting from 
insufficient knowledge concerning the importance of the osteoporosis screening (38%), 
being physically incapable of visiting the FP clinic (11.5%) or being unavailable for setting an 
appointment (23.8%)[13]. The percentage of patients that can be screened for osteoporosis 
will therefore increase when such screenings take place during the hospital admission. 
 Conducting a DXA scan during the admission is often not feasible for logistical and 
technical reasons. A peripheral DXA scan can be used to determine the BMD in the 
nursing ward during the admission[14]. Earlier studies already showed that the Calscan, a 
peripheral DXA scanner, can be used to reliably classify patients with a normal BMD and 
patients with osteoporosis[15,16]. It has also been demonstrated that a BMD measurement 
at the level of the calcaneus is as good an indicator of the risk of a future osteoporotic 
fracture as a BMD measurement of the hip or spinal column[11,17,18].  In February of 2013, 
we therefore began using the Calscan in the nursing ward of our hospital on patients 
admitted for the treatment of a low-energy fracture. If they are definitely classified as 
osteoporotic based on the Calscan T-score, a treatment was initiated. Because it proved 
impossible, for various reasons, to classify all patients during their admission – even with 
the use of the Calscan – and because a BMD measurement with a DXA scan is still the 
golden standard, all patients were also referred to the FP clinic to undergo a DXA scan. 
The final treatment plan was drawn up based on the results of this DXA scan.
 The goal of this study was to evaluate whether the percentage of patients that can be 
classified and treated will increase when the Calscan is used in the osteoporosis screening 
process. Furthermore, the study was designed to provide more insight into why and which 
patients opt out of a screening for osteoporosis.
77Osteoporosis screening among elderly patients with fractures: is there room for improvement?
Patient and method
 This study is a prospective study that compares BMD values measured with the 
Calscan to BMD values measured with the DXA scan. The study was conducted in the 
period between February and August of 2013. During this time, 213 patients over 50 years 
of age were admitted to the Traumatology department of our hospital with low-energy 
fractures. Two patients with a pathological fracture were excluded from the study. As 
a result of regular technical inspections of the Calscan, 47 patients could not undergo 
the Calscan. The study population is therefore made up of those patients for whom a 
functioning Calscan was available during their clinical treatment. In the end, 164 patients 
could be included in the study (figure 1). This type of non-intrusive observational study 
does not require ethical committee approval under Dutch legislation.  
Figure 1. Flowchart illustrating the inclusion of patients for this study
Bone mineral density measurement
 The Calscan (DXL Calscan, Demetech AB, Solna, Sweden) combines DXA with laser 
to measure the BMD at the level of the right calcaneus[19]. The Calscan automatically 
determines the optimal scanning position, making the results non-reliant on the operator. 
The Calscan must be calibrated on a daily basis using a phantom. Additionally, an automatic 
internal calibration takes place before each measurement[20]. The examination was 
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in the form of T-scores, which are immediately available. The T-score is defined as the 
standard deviation (SD) in the BMD level compared to the peak BMD level found in young 
adults[19,21]. 
 A DXA scan (Hologic Discovery A; Hologic, Massachusetts, US) was generally conducted 
in the FP clinic within 3 months of a patient’s discharge from the nursing ward. When 
patients did not show up at the FP clinic, they were contacted by phone to ask them 
again to come in. If patients still wanted to opt out of the screening, their reason for doing 
so was written down. The DXA scan measures the BMD at the level of the left hip and 
the lumbar spine (L1-4). For the purposes of this study, the lowest T-scores were used. 
The DXA scan had to be conducted by X-ray technicians and patients had to be mobile 
enough to climb onto the table to have the DXA scan done. The scanning protocol lasts 
20 minutes and the scanner was calibrated on a daily basis. 
Definition of osteoporosis
 Osteoporosis is a systemic bone affliction characterised by a lowered BMD and a loss 
of micro architecture, resulting in an elevated risk of fracture[21]. Although osteoporosis 
entails more than just a lowered BMD value, it has been demonstrated that the DXA 
scan allows for an accurate prediction of the fracture risk[21]. A DXA T-score ≤-2.5SD is 
classified as osteoporosis by the World Health Organisation (WHO) and is also used as a 
cut-off point in our study[21]. 
 To diagnose osteoporosis with the Calscan, the results of earlier studies – in which 
the cut-off points for the Calscan were determined – were used. Patients were therefore 
classified as osteoporotic based on their Calscan T-score if this score was ≤-2.9SD, unless 
it concerned a patient with a hip fracture, in which case a Calscan T-score of ≤-3.5SD 
was used[15,16]. A normal BMD was defined as a Calscan T-score >-1.4SD in patients with 
a non-hip fracture and a Calscan T-score >-1.8SD in patients with a hip fracture[15,16]. 
A lower cut-off point is used for patients with a hip fracture, compared to the general 
fracture population, because hip fracture patients are generally older. Among the elderly, 
the cut-off point for the Calscan T-score is lower[14,22]. The fact that this cut-off point 
decreases as a patient’s age increases can be derived from the relationship between the 
Z-score and the T-score: T-score = Z-score + population mean T-score[14]. The Z-score 
compares the patient’s BMD with the average BMD value for their age and gender. The 
population mean T-score is the average T-score for patients of the same age. Seeing as 
how the population mean T-score will decrease as the patients’ age increases (because 
the BMD in elderly patients decreases), T-scores will also decrease with age.
 There is an important difference between the definition of osteoporosis as employed 
by Dutch and American guidelines for osteoporosis. The American guideline sees a hip 
fracture as evidence of osteoporosis and a DXA is not advised for patients with a hip 
fracture. The Dutch guideline, on the other hand, does advise a DXA for patients with a 
hip fracture in order to classify these patients[9,23]. An important study which supports 
the American guideline is the study conducted by Lyles et al, which demonstrated that 
the mortality and the risk of subsequent fractures significantly decrease for patients with 
a hip fracture, regardless of their BMD, when they are treated with Zoledronic acid[24]. 
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 Due to the different definitions of osteoporosis used in the American and Dutch 
guidelines, this study presents the results for two groups: firstly, the general group of 
fracture patients and secondly, the group of fracture patients excluding those patients 
with a hip fracture. This is done because patients with a hip fracture might be considered 
osteoporotic if the American guideline for osteoporosis is used.
The value of the Calscan in the screening for osteoporosis
 In accordance with earlier studies in which the cut-off points for the Calscan were 
determined, the sensitivity and specificity of the cut-off points used in this study 
were calculated[15,16]. The sensitivity and specificity have to be around 90%[14]. 
Bisphosphonates were clinically administered to patients who were classified as 
osteoporotic based on their Calscan T-scores. Bisphosphonates also have side effects. That 
is why for this study, in addition to the specificity and sensitivity, the positive predictive 
value (PPV) of the Calscan T-score was also calculated.
 The Calscan’s specificity serves to rule out osteoporosis by the Calscan in non-
osteoporotic patients (DXA >-2.5SD). The specificity is calculated by dividing the number 
of non-osteoporotic patients according to the DXA with a Calscan T-score higher than 
the bottom cut-off point by the total number of patients without osteoporosis according 
to the DXA. The sensitivity of the Calscan serves to diagnose osteoporosis by the Calscan 
in patients with osteoporosis (DXA ≤-2.5SD). The sensitivity is calculated by dividing the 
number of osteoporotic patients according to the DXA with a Calscan T-score lower than 
the upper cut-off point by the total number of patients with osteoporosis according to the 
DXA. The PPV reflects the Calscan’s correct diagnosis of osteoporosis. The PPV is calculated 
by dividing the number of patients that is correctly classified as osteoporotic (DXA T-score 
≤-2.5SD) by the Calscan by the total number of patients classified as osteoporotic by the 
Calscan.
Statistical analysis
 Results are expressed as averages and percentages. A cross table was made to 
determine the specificity, sensitivity and PPV for the Calscan T-score, while 95% reliability 
intervals were also calculated. Univariate analyses were conducted to examine which 
factors relate to reasons for patients to opt out of the osteoporosis screening with a DXA 
scan. A P <0.05 was seen as significant.
Results
 Table 1 lists the general characteristics of the 164 patients. The majority of the patient 
population used for this study was female (66%), while the average age was 76 years. A 
hip fracture was the most common fracture at the FP clinic, present in 78 (48%) of the 164 
patients. In line with our expectations, patients with a hip fracture generally proved to be 




      Male       56
      Female      108
Age       76 (range 51-99)
Origin 
      Home      133
      Nursing home      31
Destination after discharge 
      Home      73
      Reactivation      63
      Nursing home      25
      Deceased       3
Delirious during admission  
      Yes       38
      No       126
Dementia 
      Yes       28
      No       136
Type of fracture 
      Hip       78
      Vertebra      19
      Wrist       3
      Subcapital humerus      8
      Upper extremity other than the wrist or subcapital humerus 15
      Lower extremity other than the hip    32
      Rib/sternum      7
      Face       2
Bone mineral density measurement (n=105) 
      Normal      19
      Osteopenia      51
      Osteoporosis      35
Reason for not visiting FP clinic (meaning: no DXA) 
      Not interested      40
      Deceased      14
      No appointment scheduled    2
      Lives outside the catchment area    2
      Detention      1
Reason for no Calscan 
      No permission given     2
      Deceased      3
      Physically impossible     10
      Discharged before Calscan could be conducted   3
Table 1. General patient characteristics and reasons why patients did not undergo a DXA or Calscan
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 Regarding the technical feasibility of the Calscan, it proved possible to conduct this 
scan on 146 (89%) patients during their admission; 10 of the 18 patients who were not 
scanned could not undergo the Calscan for physical reasons. In the end – sometimes after 
a subsequent request via telephone – DXA scans were conducted in the FP clinic on 105 
(64%) patients. The reasons why 59 patients did not visit the FP clinic are also summarised 
in table 1. The most common reason was a lack of interest (68%). Furthermore, 24% of the 
patients who did not appear in the FP clinic were deceased. This amounts to 8.5% of the 
total study population.
 Tables 2 and 3 describe the scanning data for the entire patient group, including those 
patients with a hip fracture. Both a Calscan and a DXA scan were conducted on a total 
of 101 patients. The specificity and sensitivity of the Calscan T-score were 85% (95%BI 
74-93%) and 94% (95%BI 80-99%), respectively. The Calscan’s PPV for the diagnosis of 
osteoporosis proved to be 68% (95%BI 49-83%). When patients with a hip fracture are 
left out of the equation, the specificity was 90% (95%BI 76-97%), the sensitivity 95% 
(95%BI 75-100%) and the PPV 75% (95%BI 48-93%) (tables 4 and 5). 
   DXA T-score ≤-2.5SD 
   Yes No
Calscan T-score ≤-2.9SD + non-hip fracture or  Yes 21 10
Calscan T-score ≤-3.5SD + hip fracture No 13 57
Table 2. Cross table in which osteoporosis defined by DXA is compared to osteoporosis defined by the Calscan
Specificity Calscan = 85% (95%CI 74-93%) 
Positive predictive value (PPV) = 68% (95%CI 49-83%) 
   DXA T-score ≤-2.5SD
   Yes No
Calscan T-score ≤-1.4SD + non-hip fracture or  Yes 32 40
Calscan T-score ≤-1.8SD + hip fracture No 2 27
Table 3. Cross table in which normal BMD defined by DXA is compared to normal BMD defined by the Calscan
Sensitivity Calscan = 94% (95%CI 80-99%)  
 
   DXA T-score ≤-2.5SD
   Yes No
Calscan T-score ≤-2.9SD  Yes 12 4
  No 8 35
Table 4. Cross table in which osteoporosis defined by DXA is compared to osteoporosis defined by the Calscan, 
with exclusion of all patients with a hip fracture
Specificity Calscan = 90% (95%CI 76-97%) 
Positive predictive value (PPV) = 75% (95%CI 48-93%) 
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   DXA T-score ≤-2.5SD
   Yes No
Calscan T-score ≤-1.4SD  Yes 19 24
  No 1 15
Table 5. Cross table in which normal BMD defined by DXA is compared to normal BMD defined by the Calscan, 
with exclusion of all patients with a hip fracture
Sensitivity Calscan = 95% (95%CI 75-100%)
 Of the 59 patients who did not show up at the FP clinic, 45 patients had undergone 
a Calscan: 14 patients were classified as non-osteoporotic, 17 patients were classified as 
osteoporotic and 14 patients could not be classified using the Calscan. This means that, 
with the use of the Calscan in the screening for osteoporosis, the percentage of patients 
that can be classified based on the results of the Calscan or the DXA scan can increase 
to 83% (table 6). When a hip fracture is seen as evidence of osteoporosis (in line with 
the American guideline) and these patients therefore do not have to be referred to the 
FP clinic, the number of patients that should have been screened for osteoporosis in this 
study is 86 (164-78). In total, 62 (72%) of these patients were actually screened in the FP 
clinic. On 6 of the 24 patients who were incorrectly not screened in the FP clinic no Calscan 
could be conducted during their admission. Based on the Calscan T-scores, 2 patients 
were classified as normal and 8 as osteoporotic. Eight patients who had undergone a 
Calscan could not be reliably classified based on their Calscan T-scores. This means that, if 
the Calscan had been used in the screening for osteoporosis among patients with a non-
hip fracture, 72 (84%) patients could have been reliably classified (DXA + Calscan). If, in 
the analysis of the entire group of fracture patients (including those with hip fractures), a 
hip fracture, an abnormal DXA (≤-2.5SD) or an abnormal Calscan (≤-2.9SD) would be seen 
as evidence of osteoporosis and a normal DXA (>-1.0SD) or Calscan (>-1.4SD) as evidence 
of a normal BMD, the total percentage of patients that could have been classified would 
have increased to 91% (150/164) (table 6).
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FP clinic (all fractures  FP clinic (all FP clinic (all FP clinic (all FP clinic + Calscan
including hip fractures) fractures including  fractures excluding fractures excluding  + hip fracture
  hip fractures)  hip fractures) hip fractures)
  + Calscan  + Calscan 
64%1 83%2 72%3 84%4 91%5
Table 6. Percentage of patients screened for osteoporosis
1.  The percentage of screened fracture patients (including hip fracture patients) that were screened via the FP 
clinic and classified with DXA.
2.  The percentage of screened fracture patients (including hip fracture patients) that were screened via the FP 
clinic or those patients who were classified based on the Calscan conducted during their clinical admission.
3.  The percentage of screened fracture patients (excluding hip fracture patients) that were screened via the FP 
clinic and classified with DXA.
4.  The percentage of screened fracture patients (excluding hip fracture patients) that were screened via the FP 
clinic or those patients who were classified based on the Calscan conducted during their clinical admission.
5.  The percentage of screened fracture patients (including hip fracture patients) for whom a hip fracture is seen 
as evidence of osteoporosis and the other patients were referred to the FP clinic or those patients who were 
classified based on the Calscan conducted during their clinical admission.
 When we consider the patients’ (not) visiting the FP clinic closer, we can draw the 
following conclusions. The patients who did not come to the FP clinic were significantly 
older, 80 vs 74 years, p<0.01. Patients who were admitted from home were screened for 
osteoporosis in the FP clinic significantly more often than patients admitted from a nursing 
home (p<0.01). It also became clear that patients who went home after their discharge 
were screened in the FP clinic significantly more often than patients who went back to 
the nursing home or who were admitted into a nursing home after their discharge from 
hospital (p<0.01). Patients suffering from delirium, or dementia/other cognitive disorders 
were screened in the FP clinic significantly less often; p<0.05 and p<0.01, respectively. 
Figure 2 illustrates that 47% of the patients with a hip fracture were not screened for 
osteoporosis in the FP clinic, while 79% of the patients who suffered from delirium also 
had a hip fracture.
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Figure 2. Proportions illustrating which percentage of patients appeared at the Fracture Prevention outpatient 
clinic (FP clinic) and which percentage did not
Discussion
 This study confirms the validity of the Calscan in the screening for osteoporosis. A 
sensitivity and specificity of 90% are employed in accordance with the recommendations 
of the National Osteoporosis Society concerning the use of peripheral DXA scanners[14].
 Because a treatment is initiated based on the Calscan T-score, we also considered the 
PPV an important measure of the Calscan’s validity. When the entire group of fracture 
patients over the age of 50 is analysed, the specificity of the Calscan for the ruling out 
of osteoporosis in non-osteoporotic patients proved to be 85%, while the sensitivity of 
the Calscan for the diagnosis of osteoporosis in osteoporotic patients was 94% and the 
positive predictive value for the diagnosis of osteoporosis by the Calscan was 68%. When 
just the non-hip fracture patients over the age of 50 are analysed, these values increase 
even further; the specificity, sensitivity and PPV are 90%, 95% and 75%, respectively.
 A PPV of 68-75% is low, but acceptable in our view. First and foremost, this is due to 
the relatively mild side-effects of bisphosphonates. The most common side-effects of 
bisphosphonates are musculoskeletal pain – rarely serious and/or debilitating (prevalence 
> 10%) – and gastrointestinal complaints (prevalence 1-10%)[25]. Serious side-effects 
such as osteonecrosis of the jaw are extremely rare (prevalence 0.01-0.1%)[25]. Secondly, 
the PPV can be considered acceptable because of the major advantage of treating 
patients with osteoporosis with bisphosphonates at an early stage. It is known that 
60% of subsequent fractures occur within one year of the initial fracture[26]. This is an 
important observation because it has been demonstrated that the effect of the treatment 
with bisphosphonates on the reduction of the fracture risk only becomes apparent after 
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8-11 months[27]. To prevent as many subsequent fractures as possible, it is therefore 
important to start treatment with bisphosphonates as soon as possible, preferably during 
the admission for the initial fracture.
 The third revised Dutch CBO guideline ‘Osteoporosis and Fracture Prevention’ 
recommended conducting a BMD measurement with DXA in fracture patients over the 
age of 50[9]. After implementation of this guideline, the percentage of fracture patients 
in the Netherlands screened for osteoporosis using DXA increased from 5% to an average 
of 51%[13,28,29]. In this study, we demonstrate that this percentage can increase to 
64% by actively approaching patients via telephone. However, this also means that, on 
average, half of the fracture patients in the Netherlands are still not being screened for 
osteoporosis, which is unacceptable to us.
 There are several ways to further increase this percentage. Firstly, the Calscan could be 
used in the screening for osteoporosis. The Calscan is a valid measuring instrument and 
its use can increase the percentage to 83%. Secondly, in accordance with the American 
guideline, patients with a hip fracture could be considered osteoporotic without a prior 
DXA. This method makes sense, seeing as how our results also demonstrate that nearly 
half of the patients with a hip fracture opt out of osteoporotic screening using DXA, even 
though these are often the most vulnerable patients as evidenced by our finding that 
delirium is most prevalent among patients with a hip fracture[9,24,30]. When both criteria 
are applied, the percentage of patients that have undergone a form of osteoporosis 
screening might even increase to 91%. 
 This study also demonstrates that patients who were admitted from or discharged 
to a nursing home or those who are cognitively impaired opt out of further studies 
into osteoporosis significantly more often, even though this group often includes the 
vulnerable elderly people with an elevated risk of falling down[3,31]. By offering an 
osteoporosis screening with the Calscan to these patients during their admission in the 
hospital, the percentage of vulnerable elderly patients who are screened for osteoporosis 
may increase.
 
 To summarise, we can state that the use of the DXA scan alone is not sufficient to 
allow for the proper implementation of the Dutch ‘Osteoporosis and Fracture Prevention’ 
guideline. Diagnosing osteoporosis with the Calscan and then starting treatment is a 
good alternative method. The major advantage of this strategy is that the Calscan can 
be conducted during the patient’s admission, which will also increase the percentage of 
vulnerable elderly patients who are screened for osteoporosis. Additionally, it would be 
wise to treat every elderly patient with a hip fracture for osteoporosis until its existence 
can be ruled out with a DXA scan. It is still advisable to refer all patients to the FP clinic to 
undergo a DXA scan and have their treatment path modified if necessary. 
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